Gül Cetin, Kürüm Turhan, Demir Muzaffer, Ozbay Gültaç, Vural Ozden, Iqbal Omer, Fareed Jawed
Department of Cardiology, Division of Hematology, Trakya University, Edirne, Turkey.
Clin Appl Thromb Hemost. 2004 Jan;10(1):77-9. doi: 10.1177/107602960401000114.
Essential thrombocythemia (ET) rarely causes obstruction of coronary arteries or acute myocardial infarction. Treatment of acute myocardial infarction in patients with ET may be a problem due to the important role of platelets in the pathogenesis of infarction. There is no reported case of acute myocardial infarction with essential thrombocythemia treated with a glycoprotein IIb/IIIa inhibitor. In this report, a 49-year-old woman with essential thrombocythemia, admitted with a diagnosis of acute inferolateral myocardial infarction, was treated with tirofiban, a glycoprotein IIb/IIIa receptor blocker.
原发性血小板增多症（ET）很少导致冠状动脉阻塞或急性心肌梗死。由于血小板在梗死发病机制中起重要作用，ET患者急性心肌梗死的治疗可能是个难题。目前尚无关于使用糖蛋白IIb/IIIa抑制剂治疗原发性血小板增多症合并急性心肌梗死的报道。在本报告中，一名49岁原发性血小板增多症女性患者，因诊断为急性下侧壁心肌梗死入院，接受了糖蛋白IIb/IIIa受体阻滞剂替罗非班治疗。
